Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) EBITDA Margin: 2020-2025

Historic EBITDA Margin for Apellis Pharmaceuticals (APLS) over the last 6 years, with Sep 2025 value amounting to 47.08%.

  • Apellis Pharmaceuticals' EBITDA Margin rose 7615.00% to 47.08% in Q3 2025 from the same period last year, while for Sep 2025 it was 4.50%, marking a year-over-year increase of 3976.00%. This contributed to the annual value of -25.29% for FY2024, which is 10867.00% up from last year.
  • According to the latest figures from Q3 2025, Apellis Pharmaceuticals' EBITDA Margin is 47.08%, which was up 301.67% from -23.34% recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' EBITDA Margin registered a high of 4,435.02% during Q1 2021, and its lowest value of -35,216.69% during Q2 2021.
  • For the 3-year period, Apellis Pharmaceuticals' EBITDA Margin averaged around -77.20%, with its median value being -38.54% (2024).
  • In the last 5 years, Apellis Pharmaceuticals' EBITDA Margin slumped by 3,694,340bps in 2021 and then skyrocketed by 3,425,412bps in 2022.
  • Over the past 5 years, Apellis Pharmaceuticals' EBITDA Margin (Quarterly) stood at -245.50% in 2021, then tumbled by 47,743bps to -722.94% in 2022, then skyrocketed by 66,073bps to -62.20% in 2023, then spiked by 4,502bps to -17.18% in 2024, then spiked by 7,615bps to 47.08% in 2025.
  • Its EBITDA Margin stands at 47.08% for Q3 2025, versus -23.34% for Q2 2025 and -55.14% for Q1 2025.